[{"id":"intismeran-autogene","kind":"drug","name":"Intismeran autogene","route":"/drugs/intismeran-autogene/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/drugs.ts","type":"changed","fields":[{"field":"summary","before":"\"Moderna/Merck. Phase 2b KEYNOTE-942 showed 49% reduction in recurrence or death with pembrolizumab in resected melanoma. Phase 3 INTerpath-001 (1,137 patients, stage IIB-IV resected melanoma) met RFS and DMFS endpoin...","after":"\"Intismeran is developed by Moderna and Merck. Phase 2b KEYNOTE-942 showed 49% reduction in recurrence or death with pembrolizumab in resected melanoma. Phase 3 INTerpath-001 (1,137 patients, stage IIB-IV resected mel..."}]},{"id":"intismeran-autogene","kind":"drug","name":"Intismeran autogene","route":"/drugs/intismeran-autogene/","commit":"815a2a8bae","date":"2026-09-05","author":"Jude Gomila","message":"OnCo: open map of oncology — corpus (642 objects, 14 kinds), graph, static site, API, TNBC spike","file":"src/data/drugs.ts","type":"added","fields":[{"field":"id"},{"field":"kind"},{"field":"name"},{"field":"code"},{"field":"modality"},{"field":"asOf"},{"field":"status"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"},{"field":"trials"},{"field":"drugs"},{"field":"links"}]}]